Skip to main content

Medical Services

A longer duration of treatment with the injectable formulation of buprenorphine for opioid use disorder was associated with more favorable abstinence outcomes in a newly published study.
Public health risk is forcing addiction treatment programs to rethink their typical approaches to patient drug testing at this time.
A major update to the American Society of Addiction Medicine's practice guideline for treating opioid use disorder includes the advice that unavailability or refusal of psychosocial treatment should not impede patient access to medication.
Overcoming stigma and cultivating a strong care team are among the components identified in Altarum's discussions with providers on addressing barriers to medication treatment for opioid use disorder.
An analysis of a state's publicly funded treatment for opioid use disorder found a substantially lower overdose death risk for patients receiving medication treatment, with risk for all patients increasing post-treatment.
Click here and listen to Dr. Patricia Essilfie, a physician at St. John’s Well Child, as she describes how the once limited resources and treatment plans for smokers at St. John’s, were transformed…
Back to Top